Samsung Biologics Co.,Ltd. (KRX:207940)
South Korea flag South Korea · Delayed Price · Currency is KRW
1,614,000
-43,000 (-2.60%)
At close: Mar 12, 2026

Samsung Biologics Ratios and Metrics

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
76,704,10678,463,16267,544,12554,092,24058,433,85459,746,994
Market Cap Growth
5.24%16.17%24.87%-7.43%-2.20%9.32%
Enterprise Value
76,146,11777,724,73267,525,83054,470,49157,778,38259,669,231
Last Close Price
1657000.001695000.001203851.91964096.371041477.781133459.52
PE Ratio
68.7843.9762.3563.0773.22151.80
Forward PE
43.8142.2162.1860.0882.37112.20
PS Ratio
16.8317.2219.3114.6419.4738.10
PB Ratio
10.2910.536.195.506.5011.97
P/TBV Ratio
10.3810.628.528.2310.1412.05
P/FCF Ratio
89.6091.66189.9080.60-1235.91
P/OCF Ratio
34.1234.9140.7132.4661.31131.43
PEG Ratio
1.413.323.323.323.323.45
EV/Sales Ratio
16.7117.0619.3114.7419.2538.05
EV/EBITDA Ratio
27.7328.7635.1633.9744.7285.35
EV/EBIT Ratio
36.0537.5651.1048.9158.74111.05
EV/FCF Ratio
88.9590.79189.8581.16-1234.30
Debt / Equity Ratio
0.120.120.140.190.280.26
Debt / EBITDA Ratio
0.340.340.771.191.951.85
Debt / FCF Ratio
1.081.084.182.85-26.74
Net Debt / Equity Ratio
-0.07-0.070.01-0.01-0.08-0.02
Net Debt / EBITDA Ratio
-0.21-0.210.08-0.09-0.53-0.11
Net Debt / FCF Ratio
-0.65-0.650.44-0.22179.20-1.63
Asset Turnover
0.320.320.210.230.240.22
Inventory Turnover
0.830.830.660.760.911.02
Quick Ratio
0.850.850.350.500.761.24
Current Ratio
1.741.741.431.331.542.55
Return on Equity (ROE)
17.59%17.59%10.03%9.12%11.42%8.21%
Return on Assets (ROA)
9.11%9.11%4.95%4.27%5.01%4.67%
Return on Invested Capital (ROIC)
17.20%17.57%9.57%9.48%11.77%7.98%
Return on Capital Employed (ROCE)
24.30%24.30%9.80%9.40%7.90%7.80%
Earnings Yield
2.33%2.27%1.60%1.59%1.37%0.66%
FCF Yield
1.12%1.09%0.53%1.24%-0.01%0.08%
Buyback Yield / Dilution
5.85%5.85%-53.75%-1.95%-5.51%-
Source: S&P Global Market Intelligence. Standard template. Financial Sources.